Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed.
The report by Oddo and colleagues in this issue of Neuron demonstrates for the first time that clearance of amyloid also results in the removal of early-stage tau pathology in mice that develop both amyloid plaques and neurofibrillary tangles (NFT), the two hallmark lesions of Alzheimer's disease (AD). This result supports a primary role for Abeta in AD etiology.
Hutton
Michael
M
Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.
McGowan
Eileen
E
D000544:Alzheimer Disease / Q000276:immunology* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D023582:Alzheimer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000276:immunology* / Q000502:physiology; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D016875:tau Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000633:toxicity*
D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D000906:Antibodies; D016875:tau Proteins